Gilead Sciences, Inc. (GILD)
Nasdaq · Healthcare · Drug Manufacturers - General
$144.63−0.08%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $179B
- Forward P/E
- 14.6
- Dividend yield
- 2.3%
- 52-week range
- $112.82 – $157.29
- 52-week change
- +23.94%
- EPS (trailing)
- −$2.65
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $29.4B (+2.40%)
- Net income
- $8.5B
- Operating margin
- 34.0%
- Diluted EPS
- $6.78
- Free cash flow
- $9.5B
From the company’s annual report on SEC EDGAR.
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
Headquarters: Foster City, United States · 17,000 employees · gilead.com